Pre-treatment hormonal receptor status and Ki67 index predict pathologic complete response to neoadjuvant trastuzumab/taxanes but not disease-free survival in HER2-positive breast cancer patients. (Q54513997)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Pre-treatment hormonal receptor status and Ki67 index predict pathologic complete response to neoadjuvant trastuzumab/taxanes but not disease-free survival in HER2-positive breast cancer patients.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22547076

Pre-treatment hormonal receptor status and Ki67 index predict pathologic complete response to neoadjuvant trastuzumab/taxanes but not disease-free survival in HER2-positive breast cancer patients. (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22547076

author name string

Guo-Chun Zhang

1

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22547076

Xue-Ke Qian

2

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22547076

Zi-Bai Guo

3

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22547076

Chong-Yang Ren

4

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22547076

Meng Yao

5

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22547076

Xue-Rui Li

6

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22547076

Kun Wang

7

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22547076

Jian Zu

8

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22547076

Ning Liao

9

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22547076

publication date

1 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22547076

Medical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22547076

29

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22547076

5

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22547076

3222-3231

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22547076

HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0242-8

21 January 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0242-8

21 January 2018

Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0242-8

21 January 2018

Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0242-8

21 January 2018

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0242-8

21 January 2018

Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0242-8

21 January 2018

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0242-8

21 January 2018

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0242-8

21 January 2018

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0242-8

21 January 2018

Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0242-8

21 January 2018

Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0242-8

21 January 2018

A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0242-8

21 January 2018

HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS component.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0242-8

21 January 2018

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0242-8

21 January 2018

Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0242-8

21 January 2018

MIB-1 proliferative activity in invasive breast cancer measured by image analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0242-8

21 January 2018

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0242-8

21 January 2018

Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0242-8

21 January 2018

Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0242-8

21 January 2018

Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0242-8

21 January 2018

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0242-8

21 January 2018

Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/22547076

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22547076

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22547076

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12032-012-0242-8

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22547076

release_la3nhqpprzdplaml6jjt7iuax4

1 reference

https://api.fatcat.wiki/v0/release/la3nhqpprzdplaml6jjt7iuax4

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22547076

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54513997&oldid=2212496648"